These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26659914)

  • 1. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
    Broijl A; Kersten MJ; Alemayehu WG; Levin MD; de Weerdt O; Vellenga E; Meijer E; Wittebol S; Tanis BC; Cornelisse PB; Stevens-Kroef M; Bos GM; Wijermans PW; Lokhorst H; Sonneveld P
    Haematologica; 2016 Apr; 101(4):e149-52. PubMed ID: 26659914
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
    Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
    Jacobus SJ; Rajkumar SV; Weiss M; Stewart AK; Stadtmauer EA; Callander NS; Dreosti LM; Lacy MQ; Fonseca R
    Blood Cancer J; 2016 Jul; 6(7):e448. PubMed ID: 27471864
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
    Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
    Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
    Fonseca R; Rajkumar SV
    Clin Lymphoma Myeloma; 2008 Oct; 8(5):315-7. PubMed ID: 18854289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.
    Mian M; Pescosta N; Badiali S; Cappelletto PC; Marcheselli L; Luminari S; Patriarca F; Zambello R; Pascarella A; Tagariello G; Marabese A; Mondello P; Billio A; Cortelazzo S
    Br J Haematol; 2019 Jun; 185(5):944-947. PubMed ID: 30478966
    [No Abstract]   [Full Text] [Related]  

  • 9. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
    Paludo J; Mikhael JR; LaPlant BR; Halvorson AE; Kumar S; Gertz MA; Hayman SR; Buadi FK; Dispenzieri A; Lust JA; Kapoor P; Leung N; Russell SJ; Dingli D; Go RS; Lin Y; Gonsalves WI; Fonseca R; Bergsagel PL; Roy V; Sher T; Chanan-Khan AA; Ailawadhi S; Stewart AK; Reeder CB; Richardson PG; Rajkumar SV; Lacy MQ
    Blood; 2017 Sep; 130(10):1198-1204. PubMed ID: 28684537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
    Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient].
    Uchida T; Inoue M; Hua J; Hagihara M
    Rinsho Ketsueki; 2016 May; 57(5):613-7. PubMed ID: 27263787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
    Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
    Takemori N; Imai G; Hoshino K; Ooi A; Kojima M
    J Med Case Rep; 2018 Feb; 12(1):40. PubMed ID: 29454372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
    Terpos E; Christoulas D; Kastritis E; Katodritou E; Papatheodorou A; Pouli A; Kyrtsonis MC; Michalis E; Papanikolaou X; Gkotzamanidou M; Koulieris E; Gavriatopoulou M; Zervas K; Dimopoulos MA;
    Am J Hematol; 2014 Jan; 89(1):34-40. PubMed ID: 23983166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
    San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
    Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
    Kukreti V; Masih-Khan E; Young T; Chu CM; Jiang H; Trudel S; Chen C; Jimenez-Zepeda V; Reece DE
    Am J Hematol; 2013 Apr; 88(4):337-8. PubMed ID: 23494911
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
    Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
    Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.